T1? MRI OF PATIENTS WITH ALZHEIMER?S DISEASE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 阿尔茨海默病(AD)是一种神经退行性疾病，是痴呆症最常见的形式 在老年人身上发现。目前尚无治疗阿尔茨海默病的方法，部分原因是缺乏早期 疾病的诊断。受阿尔茨海默病影响的大脑的早期变化被认为发生在 生化指标与神经原纤维缠结(NFTs)和老年斑(SPS)的生长 导致大分子退化和细胞死亡。目前最先进的磁共振成像技术 只能测量疾病进展后期发生的大体形态变化， 然而，存在另一种称为T1的MRI对比度。早期大分子变化 将改变散装水的T1？松弛时间，从而在体内更早地观察AD的进展。 在本项目中，T1？松弛时间是在AD、轻度认知障碍(MCI)和 对照人群评估T1诊断AD的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's Disease (AD) is a neurodegenerative disease that is the most common form of dementia found in the elderly. Currently, there is no existing treatment for AD in part due to lack of early diagnosis of the disease. Early changes in AD affected brains are thought to occur on a biochemical scale with the growth of neurofibrilary tangles (NFTs) and senile plaques (SPs) which lead to macromolecular deterioration and cell death. Current state of the art MRI techniques can only measure gross morphological changes that occur late in the disease progression, however an alternate MRI contrast exists which is called T1¿. Early macromolecular changes will alter the bulk water T1¿ relaxation times providing an earlier in vivo look at AD progression. In this project, T1¿ relaxation times are measured in AD, mildly cognitively impaired (MCI) and control populations to assess the ability of T1¿ to diagnose AD.